CPSA Europe 2019

Meeting Programme

Updated 18 January 2019

Tuesday | Wednesday | Thursday | Friday

Tuesday February 5

1:00 PM - 4:30 PM

The King's Room

WORKSHOP

1:00 PM - 4:30 PM

Magdalene Room

WORKSHOP

If Our Own Scientific Community Does Not Have the Answer Where Do We Look?

Workshop Leader: Jason Wrigley, Merck (MilliporeSigma in USA/Canada)

This workshop starts with the premise that as specialists in a particular field we are not always necessarily the best people to develop and implement novel technological approaches. As such, it will provide an overview of where we currently are with this and what we do. This will be followed by an open floor discussion to see where we could go and look for ideas and solutions. This session does not have the answers but is looking to the audience to think differently and brainstorm where we might go and look for some answers/solutions. A fun and serious discussions will be concluded with action points for follow up to see if we really can find some novel (to our industry!) solutions.

If you have a topic/area of interest you would like to include please inform us before the meeting – Think big!!

1:00 PM - 4:30 PM

The Queen's Room

WORKSHOP

The Future of Personalized Healthcare:
Integrated Solutions

Workshop Leader: Emily Ehrenfeld, New Objective

This solutions-based workshop will explore how we generate and utilize quantitative data for human healthcare and wellbeing. Established workflows for the generation of quantitative analytical data used for decision making by clinicians, pharmaceutical companies, central clinical laboratories and academics have remained essentially unchanged for decades. This approach has suited the established means of one size fits all approach to delivering healthcare. However, this approach is no longer ideal, or indeed sustainable. Personalized medicines and treatments are increasingly becoming the norm. Further, technologies are enabling patient sampling and subsequent analysis to be performed in locations and with technologies that are more patient centric and importantly, many subjects are taking a more active interest in their own medical data and the decisions resulting from it. This paradigm shift calls for a change from the established workflows. This workshop will explore these changes, their implications and what a new normal might look like in 5-10 years time. We welcome you to join our discussion.

Panel Discussion:
Matt Barfield, GlaxoSmithKline
Kevin Bateman, Merck
Ute Gerhard, University of Hertfordshire
Bernhard Nemec, Prolab Instruments
Pawanbir Singh, Trajan Scientific and Medical
Neil Spooner, Spooner Bioanalytical Services

6:00 PM - 9:00 pm

The College Suite

Welcome Reception

Say hello to old friends and introduce yourself to new!

Refreshments and light buffet served.

Wednesday February 6

7:00 AM - 8:30 AM

 

Registration & Breakfast

Breakfast in the Bridge Restaurant
Registration - Main Lobby (7:30 am)

8:30 AM - 8:45 AM

The University Suite

Welcome & Opening Remarks

Mike Lee

Welcome
Mike Lee
Milestone Development Services

Neil Spooner

Format, Objectives, Opening Remarks
Neil Spooner
Spooner Bioanalytical Solutions

Ismael Zamora


Ismael Zamora
Molecular Discovery

8:45 am - 9:45 am

The University Suite

Plenary Lecture

Plenary Speaker

What Solutions are Needed to Meet the Health Needs of Future Generations?

Hitesh Pandya, GlaxoSmithKline

The terms health and healthcare encompass people, populations, systems, processes and structures.

Innovation, change and investment have been the hallmarks of health and healthcare delivery over the past 200 years. Compared to 1800’s, people now live much longer. They are also less likely to die in early life as a result of complications at birth or lethal disorders such as cystic fibrosis and can live with a relatively good quality of life with chronic conditions such as diabetes and asthma.

While spending on health and healthcare will continue at current levels for the foreseeable future, it seems unlikely that present levels of spending can afford the innovations and change required to meet the health needs of people with multiple chronic diseases living longer. One emerging unmet need in healthcare is complexity. Complexity in health refers to managing people with multiple disorders and analysing the vast and disparate amounts of data about them (demography, lifestyle, genetics, laboratory tests etc) and their ailment(s) to determine optimal treatments. Can we reduce the number of women needing costly IVF therapy to have babies? Am I over-eating and what foods will stop me getting fat? How can I sleep better for better mental health? How well we deal with the challenges of healthcare has always impacted on society. This presentation outlines a future where people are empowered to manage their health firstly to keep them from becoming ill and if unwell, how best to manage their ailments in the community. What solutions do we ned to make this happen?

9:45 AM - 11:15 am

The University Suite

Session 1
Symposium Session

Pushing the Boundaries of Sample Collection – Near and Small

Discussion Leaders: Matt Barfield, GlaxoSmithKline; Emily Ehrenfeld, New Objective

GSK Centre for FTIH Research—A Patients, Clinicians and Analysts Perspective
James Ritter, Pauline Kitchiner, Bill Davis
GSK Clinical Unit, Addenbrooke’s Hospital

Patient Centric Sampling and Analysis: How Might We Progress the Agenda and What Might the Outcome Look Like?
Neil Spooner, Spooner Bioanalytical Solutions

Why Aren’t We Doing patient Centric Sampling?
Kevin Bateman, MSD (Merck & Co. in USA/Canada)

11:15 pm - 12:45 pm

The University Suite

Session 2
Symposium Session

Emerging Technologies to Enable a Paradigm Shift from "Sick Care" to "Health Care"

Discussion Leaders: Emre Isin, UCB; Pawanbir Singh, Trajan Scientific and Medical

The primary goal for pharmaceutical industry is to develop medicines with the right exposure, reach the right target and treat the right patient. However, in the present information rich world, the ultimate objective is not only to control symptoms and treat disease but provision of technologies that facilitate both disease prevention and disease management. The enormity of this objective requires a transformative change. On one hand, there is the need to develop and have access to novel technologies which accelerate the drug development process and on the other, novel tools that enable a prevention model by focusing on forestalling disease development before clinical manifestation.

The objective of this session is to discuss emerging technologies and avenues to facilitate a paradigm shift from "sick care” to “health care"

Utilising a Therapeutic Drug Monitoring Approach for the Treatment of Childhood Cancer Patients in the UK – Development of a National Programme of Work
Gareth Veal, University of Newcastle

From Bench to Bedside: The Growing Use of MS-Based Molecular Profiling in Intraoperative Diagnostics
Tiffany Siegel, The Maastricht Multimodal Molecular Imaging Institute (M4I), Maastricht University

12:45 PM - 2:15 pm

The College Suite

Sponsored Lunch & Roundtable

The Future of Personalised Healthcare: Integrated Solutions – Mapping a Path Forward for Microsampling and Separations

Discussion Leaders: Matt Barfield, GlaxoSmithKline;
Neil Spooner, Spooner Bioanalytical Solutions; Mike Lee, Milestone Development; Emily Ehrenfeld, New Objective

2:30 pm - 4:00 pm

The University Suite

Workshop

Developing Novel Analytical Technologies:
Understanding the Requirements of the Patient

Workshop Leaders: Britta Bonn, AstraZeneca; Ute Gerhard, University of Hertfordshire; Emre Isin, UCB; Darragh Murnane, University of Hertfordshire

Have you ever stopped to think about how many new technologies you have seen presented at conferences as clinical diagnostic and monitoring tools that have failed to take root? What about those blank faces staring at you as you discuss sampling errors, matrix interference effects and wonder why the clinical laboratory doesn't want to buy your instrument?

In this workshop session you will have the opportunity to hear from and talk with a patient about what drives their decision-making in their healthcare management. You will also have the opportunity to hear about what a clinician really needs to be able to make clinical decisions that matter to them. Further, you will have the opportunity to discuss with clinicians and patients about how well-designed analytical tools can transform lives, not just clinical care.

4:00 pm - 5:30 pm

The University Suite

Session 3
Symposium Session

Data in the 21st Century:  Who owns it? Who can access it?  Who pays for it? Who believes it?

Discussion Leaders: Laura Dormer, Future Science / Bioanalysis; Shane Needham, Alturas Analytics

The Publisher Perspective
Laura Dormer, Future Science Group

The Pharma Perspective
Chris Rains, Shire Pharmaceuticals

5:30 pm

The University Suite

CPSA EUROPE GROUP PHOTO

Please gather together to capture the 2nd Annual CPSA Europe meeting with a group photo–including organizers, speakers, attendees–everyone!

6:00 pm - 8:00 pm

The College Suite

Reception & Dinner

Thursday February 7

7:00 AM - 8:30 AM

 

Registration & Breakfast

Breakfast in the Bridge Restaurant
Registration - Main Lobby (7:30 am)

8:30 am

The University Suite

Opening Remarks

Mike Lee, Milestone Development Services
Neil Spooner, Spooner Bioanalytical Solutions
Isma Zamora, Molecular Discovery

8:30 am - 10:00 am

The University Suite

Session 4
SYMPOSIUM SESSION

Moving the Needle – Intact Biomolecule Quantification

Discussion Leaders: David Browne, PRA Health Sciences; Rob Buco, Waters Corporation

10:00 am - 11:30 Am

The University Suite

Session 5
Symposium Session

Using Technology to Improve Medical Adherence?

Discussion Leaders: Kevin Bateman, Merck; James Rudge, Neoteryx

Identifying Medication Nonadherence Could Save £Billions
Graham Lawson, De Montfort University

Forming a patient-doctor alliance through home TDM
J.J. Kim, Nottingham Children's Hospital

The Fallacy of Adherence in Clinical Trials, and the Value of Technology as an Impartial Observer
Matt Moyer, MSD (Merck & Co. in USA/Canada)

On-Demand High-Content Drug Adherence and Biomarker Monitoring
Erwin Berthier, Tasso Inc.

11:30 am - 1:00 pm

The University Suite

Session 6
Symposium Session

Extraordinary Measures - Are We Measuring the Right Thing?

Discussion Leader: Ute Gerhard, University of Hertfordshire; Darragh Murnane, University of University of Hertfordshire; Christophe Stove, University of Ghent

The objective of the session will explore the challenges involved in measuring the right molecule, from the right matrix at the appropriate time points to really understand DMPK-PD phenomena.

"Hiding in Plain Sight"
Nanoparticle Bioanalysis - Can't See the Wood for the Tree
Aaron Smith, AstraZeneca

"Gone Girl"
A Disconnect Between What’s Easy to Measure and Efficacy
Deanne Rudd, Merck

1:00 am - 2:30 pm

The University Suite

Sponsored Lunch & Roundtable

Patient Centric Diagnostics – From Bedside Back to Bench

How can we flip the common term "from bench to bedside" to be a more patient centric "Bedside Back to Bench"? Industry leaders will then present an overview of the current landscape. We will then open the discussion to try and find pragmatic solutions by collaboration

Introduction
Jason Wrigley, Merck

Story So Far for Cancer Diagnostics
Steven Pennington, Atturos

Innovative "Real Time" Decisions - Bench at the Bedside
Jenny Royle, digitalECMT

2:30 pm - 4:00 pm

The University Suite

Workshop

Evolving Ideas into Deployable New Technologies—Breaking Down Barriers

Workshop Leaders: James Rudge, Neoteryx; Amanda Wilson, AstraZeneca

Big data, AI, 3-D printing and a connected world are making it possible to have the spark of an idea in one field of science and have a ready-made prototype produced thousands of miles away - even within hours of the products conception! Furthermore, modern technology is such that the idea can propagate into other fields which are then potentially useful for many other applications including the original intended use. But how do we move to deploying these inventions into adopted novel workflows? What barriers need to be overcome to make this so? In this session, we are exploring 3 different areas where our modern world impacts the evolution of deployable technologies and how these technologies in-turn have the potential to evolve future bioanalytical and healthcare solutions.

4:00 pm - 5:30 pm

The University Suite

Session 7

Symposium Session

Biomarkers – An Emerging Role in Patient Centric Drug Development

Discussion Leaders: Britta Bonn, AstraZeneca;
Axel Pähler, Roche

From Animals to Patients and Back: Case Studies For Translational Biomarkers
Axel Pähler, Roche

PExA - A Non-Invasive Technique to Sample Biomarkers from the Lung
Jörgen Östling, PExA

Panel Discussion:
Translational Biomarkers Status and Trends
Britta Bonn, AstraZeneca
Jörgen Östling, PExA
Axel Pähler, Roche
Neil Spooner, Spooner Bioanalytical Solutions

6:00 pm - 8:00 pm

The College Suite

Sponsored Reception & Dinner

The Future of Personalised Healthcare:
Integrated Solutions – Mapping a Path Forward for Sample Preparation and Data

Discussion Leaders: Matt Barfield, GlaxoSmithKline;
Neil Spooner, Spooner Bioanalytical Solutions; Mike Lee, Milestone Development; Emily Ehrenfeld, New Objective

Friday February 8

7:00 AM - 8:30 AM

The Bridge Restaurant

Registration & Breakfast

Breakfast in the Bridge Restaurant
Registration - Main Lobby (7:30 am)

8:30 am

The Peterhouse Room

Opening Remarks

Mike Lee, Milestone Development Services
Neil Spooner, Spooner Bioanalytical Solutions
Isma Zamora, Molecular Discovery

8:30 am - 10:00 am

The Peterhouse Room

Session 8
Symposium Session

Big Data Science Guiding Patient Care

Discussion Leaders: Amanda Wilson, AstraZeneca; Jason Wrigley, Merck (MilliporeSigma in USA/Canada)

The widespread application of omics and big data science is facilitating the transition from conventional to personalised medicine. Industry has become data intensive and there are unprecedented opportunities to utilise omics data integration to address biological questions that can improve patient outcomes.

Short presentations from Academia and Pharma to showcase the big data science technology and application in making drug development and patient care decisions will be given. This session will then allow science leaders to engage in an open format panel discussion to explore this area more fully.

If Big Data is the Answer, What Was the Question?
Ian Wilson, Imperial College

  • (Metabon)Omic data from biobanking, epidemiology etc.—What can we extract?
  • What might "Fit for purpose data" collection look like?

Mass Spectrometry Tissue Imaging: Linking Drug Efficacy & Safety with Deep Cellular Phenotyping
Richard Goodwin, AstraZeneca

Patients Front and Centre: Enabling Personalized Healthcare with Data from Individuals and Populations
Ian Wilson, Imperial College

  • Are you taking the tablets? - are you sure? Taking guesswork out of the clinic with, targeted and specific multi-analyte drug (100's) analysis
  • And what else are you taking that you haven't told me about? Semi-targeted analysis for OTC, herbal or obtained via the internet drugs that could interfere with data interpretation on patient outcomes made using the same multi-targeted assays
  • Do we need these data?

10:00 am - 11:30 pm

The Peterhouse Room

Session 9
Symposium Session

Mass Spectrometry Imaging: Emerging Advancements and Applications

Discussion Leaders: Ismael Zamora, Molecular Discovery; Sara Tortorella, Molecular Horizon

Mass Spectrometry Imaging in the Pharmaceutical Industry – Continuum from Enzyme to Patient
Peter Marshall, GlaxoSmithKline

What's going on in Computer Vision today and Why You Might Care
Vadim Fedorov, Lead Molecular Design

Digging Into the Unknown Unknowns: Data Analytics Challenges of Mass Spectrometry Imaging
Sara Tortorella, Molecular Horizon

11:30 pm - 1:00 pm

The Peterhouse Room

Session 10
Symposium Session

Current Models for Performing Quantitative Bioanalysis in Pharma and CROs – Are They Working?

Discussion Leaders: Liz Thomas, Alderley Analytical;
Neil Spooner, Spooner Bioanalytical Solutions

Pharmaceutical companies are currently wedded to outsourcing the majority of their quantitative bioanalytical work. This helps them to minimise their internal costs (capital, labour, infrastructure) and deal with the peaks and troughs in workload. For Contract Research Organisations, this would appear to be a time of feast. However, as there is so much competition in the sector and Pharma are driving costs down, the equation is not so simple. Add to this the fact that CROs need to make a profit. Does this mean that the quality vs cost equation is currently out of kilter for this process?

The session will explore the above premise through 10 min presentations from experts in the field and then look at what the solutions might be with a panel discussion.

A View from Pharma
Scott Summerfield, GlaxoSmithKline

A View from CROs
Jane Allanson, York Bioanalytical Solutions (Unilabs)

Bioanalysis 4.0: Is Automation Part of the Solution?
Nathan Hawkins, Anatune

Pharma and CRO: Could a Technology Vendor Assist in Global Harmonisation
Jason Wrigley, Merck (MilliporeSigma in USA/Canada)

1:00 pm

The Peterhouse Room

Closing Remarks

Neil Spooner, Spooner Bioanalytical Solutions
Ismael Zamora, Molecular Discovery
Mike Lee, Milestone Development Services